Rosetta Genomics to receive U.S. patent for cancer origin assay Rosetta Genomics announced that the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering the method of use of a core element of Rosetta Genomics' microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer. The issued claims for U.S. Patent Application No. 13/167,489 is entitled "Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples."
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.